# MYC targeting by OMO-103 in solid tumors: a phase 1 trial

*PRI Rank #18 · Topics and Trends in Most Cited Cancer Genomics and Diagnostics Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/cancer-genomics-and-diagnostics/2026/rank-18*

| Field | Value |
| --- | --- |
| Rank | #18 |
| 18m citations | 94 |
| Journal | Nature Medicine |
| Year | 2024 |
| DOI | 10.1038/s41591-024-02805-1 |
| Corresponding authors | Laura Soucek |
| Institution | Vall d’Hebron Institute of Oncology, Spain |

**Ranking page:** [Topics and Trends in Most Cited Cancer Genomics and Diagnostics Papers, Class of 2026](https://pri.pepkio.com/top-papers/cancer-genomics-and-diagnostics/2026)

**Paper link:** [10.1038/s41591-024-02805-1](https://doi.org/10.1038/s41591-024-02805-1)

## Topics

MYC oncogene · MYC inhibitor · OMO-103 · miniprotein · Solid tumors · phase 1 clinical trial · dose escalation · 3+3 design · dose-limiting toxicity · pharmacokinetics · recommended phase 2 dose · Infusion reactions · adverse events · stable disease · Response evaluation criteria in solid tumors · Tumor regression · Transcriptomics · target engagement · Tumor biopsy · pharmacodynamic markers · predictive response markers · soluble factors · nonlinear pharmacokinetics · tissue saturation · terminal half-life · intravenous administration · single-agent therapy · advanced solid tumors · oncogene targeting · Undruggable targets · transcriptional programs · Cancer progression · tumor maintenance · antitumor activity · computed tomography · Cancer progression · safety and tolerability

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer Genomics and Diagnostics Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-genomics-and-diagnostics/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```